Dacetuzumab has been evaluated for treating multiple myeloma, non-Hodgkin lymphoma, leukemia, chronic lymphocytic leukemia, and diffuse large B-cell lymphoma as an anti-CD40 antibody inducing cytotoxicity in multiple myeloma cells. The DrugMonitor™ Anti-Dacetuzumab Antibody (VS-1224-YC331) is an anti-drug antibody (ADA) against Dacetuzumab. This drug-based antibody is raised in mice immunized with the Dacetuzumab. The anti-Dacetuzumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Dacetuzumab in samples.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Afuco™ Anti-CD40 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-152)This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CD40. It is a humanized monoclonal antibody being developed for the treatment of CD40-positive cancers like non-Hodgkin's lymphoma and hematological malignancies.
There are currently no Customer reviews or questions for VS-1224-YC331. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.